Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 3

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

Search:
in the keywords:  IGF-I
help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Content available remote

Prevalence and recurrence rate of colonic lesions in acromegalic patients

100%
Berker D., Tutuncu Y., Isik S., Aydin Y., Ozuguz U., Akbaba G., Yuksel O., Erden G., Altiparmak E., Guler S.
Open Medicine
|
2010
|
vol. 5
|
issue 6
704-711
EN
Acromegaly is associated with an increased prevalence of colonic polyps. The aim of this study was to evaluate the prevalence and recurrence rate of colonic polyps in acromegalic patients. Ninety-six acromegalic patients and 100 irritable bowel syndrome patients (IBS) were enrolled in the study. Twenty patients who were cured exclusively by surgery, and 20 patients that could not be hormonally controlled were re-examined colonoscopically after 36 months. Twenty-nine of 96 acromegalic patients (30.2%) had colonic polyps. In the IBS group, 10 (10.0%) had colonic polyps. The prevalence of colonic polyps was significantly higher in acromegaly. The group of acromegalic patients with and without polyps did not differ significantly with regard to plasma GH, IGF-I, fasting insulin levels and glycemic status. The presence of colonic polyps was correlated with increased patient age and male gender. We did not observe a difference in terms of polyp recurrence frequencies in the patients cured by surgery compared to uncontrolled patients. Acromegalic patients have a higher prevalence of colonic polyps than that of control subjects. We could not identify any factors that could predict polyps within the acromegalic patients - but age and male sex.
2

From neoplastic neural development to gene therapy of brain tumors ? IGF-I antisense and triple helix approaches

100%
Trojan J.
Biotechnologia
|
2003
|
issue 2
280-289
EN
IGF-I, insulin ? like growth factor I, seems to play a major role in the normal and tumoral development of the nervous system. Glioblastoma is the most frequent brain tumor in man and is usually fatal. Both human and rat glioma cells express high amounts of IGF-I. When rat glioma cells are transfected with vectors expressing either IGF-I antisense RNA or inducing IGF RNA ? DNA triple helix, the synthesis of IGF-I was stopped on translation or transcription levels, respectively. Down-regulation in the expression of IGF-I coincides with the reappearance of B-7 and MHC class I antigens at the surface of transfected cells. When injected subcutaneously, the transfected cancer cells initiate an immune reaction involving CD8+ lymphocytes, followed by tumor regression. The ?anti-gene? strategy for clinical therapy of glioblastoma, and other tumors expressing IGF-I such hepatomas were introduced in University Hospitals of Cleveland (USA), Shanghai ( China) , Krakow and Bydgoszcz (Poland).
3
Content available remote

IGF-I: from diagnostic to triple-helix gene therapy of solid tumors.

86%
Trojan L. A., Kopinski P., Wei M. X., Ly A., Glogowska A., Czarny J., Shevelev A., Przewlocki R., Henin D., Trojan J.
|
2002
|
vol. 49
|
issue 4
979-990
EN
Alterations in the expression of growth factors and their receptors are associated with the growth and development of human tumors. One such growth factor is IGF-I (insulin-like growth factor I ), a 70-amino-acid polypeptide expressed in many tissues, including brain. IGF-I is also expressed at high levels in some nervous system-derived tumors, especially in glioblastoma. When using IGF-I as a diagnostic marker, 17 different tumors are considered as expressing the IGF-I gene. Malignant glioma, the most common human brain cancer, is usually fatal. Average survival is less than one year. Our strategy of gene therapy for the treatment of gliomas and other solid tumors is based on: 1) diagnostic using IGF-I gene expression as a differential marker, and 2) application of "triple-helix anti-IGF-I " therapy. In the latter approach, tumor cells are transfected with a vector, which encodes an oligoribonucleotide - an RNA strand containing oligopurine sequence which might be capable of forming a triple helix with an oligopurine and/or oligopyrimidine sequence of the promotor of IGF-I gene (RNA-IGF-I DNA triple helix). Human tumor cells transfected in vitro become down-regulated in the production of IGF-I and present immunogenic (MHC-I and B7 expression) and apoptotic characteristics. Similar results were obtained when IGF-I antisense strategy was applied. In both strategies the transfected cells reimplanted in vivo lose tumorigenicity and elicit tumor specific immunity which leads to elimination of established tumors.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.